Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | China | Patent: 1 | ||
2 | IT | Patent: 1 | ||
3 | China | Patent: 1 | ||
4 | Hunan Sheng, China | Patent: 1 | ||
5 | China | Patent: 1 |
Top 5 New Entrants companies in Argatroban
by Most Patent Filing In 3 Years in the world in 2018
The Argatroban top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 3 Years Argatroban New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2018, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.
Page generation time:
May 08 2025